Antibiotic Choice for Children Hospitalized With Pneumonia and Adherence to National Guidelines

Derek J. Williams, MD, MPH\textsuperscript{a}, Kathryn M. Edwards, MD\textsuperscript{b}, Wesley H. Self, MD, MPH\textsuperscript{c}, Yuwei Zhu, MD, MSc\textsuperscript{d}, Krow Ampofo, MD\textsuperscript{e}, Andrew T. Pavia, MD\textsuperscript{f}, Adam L. Hersh, MD, PhD\textsuperscript{g}, Wesley H. Self, MD, MPH\textsuperscript{d}, Yuwei Zhu, MD, MSc\textsuperscript{d}, Krow Ampofo, MD\textsuperscript{e}, Andrew T. Pavia, MD\textsuperscript{f}, Adam L. Hersh, MD, PhD\textsuperscript{g}, Sandra R. Arnold, MD\textsuperscript{h}, Jonathan A. McCullers, MD\textsuperscript{h}, Lauri A. Hicks, DO\textsuperscript{i}, Anna M. Bramley, MPH\textsuperscript{j}, Seema Jain, MD\textsuperscript{j}, Carlos G. Grijalva, MD, MPH\textsuperscript{k}

abstract

INTRODUCTION: The 2011 national guidelines for the management of childhood community-acquired pneumonia (CAP) recommended narrow-spectrum antibiotics (eg, ampicillin) for most children hospitalized with CAP. We assessed the impact of these guidelines on antibiotic prescribing at 3 children’s hospitals.

METHODS: Children hospitalized with clinical and radiographic CAP were enrolled from January 1, 2010, through June 30, 2012, at 3 hospitals in Tennessee and Utah as part of the Centers for Disease Control and Prevention Etiology of Pneumonia in the Community study. Antibiotic selection was determined by the treating provider. The impact of the guidelines and hospital-level implementation efforts was determined by assessing the monthly percentage of enrolled children receiving third-generation cephalosporins or penicillin/ampicillin. Segmented linear regression was used to compare observed antibiotic selection in the postguideline period with expected antibiotic use projected from preguideline months.

RESULTS: Overall, 2121 children were included. During the preguideline period, 52.8% (interquartile range 47.8–56.6) of children with CAP received third-generation cephalosporins, whereas 2.7% (2.1, 7.0) received penicillin/ampicillin. By 9 months postguidelines, third-generation cephalosporin use declined (absolute difference $-212.4\% \ (95\%$ confidence interval $-19.8\% \text{ to } -5.1\%$)), whereas penicillin/ampicillin use increased (absolute difference $11.3\% \ (4.3\% \text{– } 18.3\%$)). The most substantial changes were noted at those institutions that implemented guideline-related dissemination activities.

CONCLUSIONS: After publication of national guidelines, third-generation cephalosporin use declined and penicillin/ampicillin use increased among children hospitalized with CAP. Changes were more apparent among those institutions that proactively disseminated the guidelines, underscoring the importance of local efforts for timely implementation of guideline recommendations.

WHAT’S KNOWN ON THIS SUBJECT: The 2011 national guidelines for the management of pediatric community-acquired pneumonia recommended narrow-spectrum antibiotic therapy (eg, ampicillin) for most children hospitalized with pneumonia. Before the release of the guidelines, the use of broader-spectrum antibiotics (eg, third-generation cephalosporins) was much more common.

WHAT THIS STUDY ADDS: After release of the guidelines, third-generation cephalosporin use declined and penicillin/ampicillin use increased among children hospitalized with pneumonia. Changes were most apparent among institutions that proactively disseminated the guidelines, underscoring the importance of local efforts for timely guideline implementation.
To assist clinicians in caring for children with community-acquired pneumonia (CAP), a committee convened by the Pediatric Infectious Diseases Society (PIDS) and the Infectious Diseases Society of America (IDSA) comprehensively reviewed best available evidence for the management of childhood CAP, culminating in the release of the first national consensus management guidelines in August 2011. Antibiotic selection was 1 of several major areas targeted by the committee. Recommendations emphasized the use of a single, narrow-spectrum antibiotic (ie, penicillin/amoxicillin) for vaccinated children hospitalized with uncomplicated CAP. Evidence cited in support of this recommendation included the finding that Streptococcus pneumoniae was the most common bacterial pathogen causing pediatric CAP, and observed declines in penicillin-resistant pneumococcal disease after conjugate vaccine introduction, and demonstrated effectiveness of high-dose penicillin therapy for relatively resistant pneumococcal infections outside the central nervous system.

Despite the strength of evidence supporting narrow-spectrum therapy, broader-spectrum antibiotics were much more commonly used before the release of the guidelines. A recent study demonstrated that third-generation cephalosporins accounted for nearly 90% of prescribing for CAP at 29 U.S. children’s hospitals between 2005 and 2010. Thus, the recommendation for narrow-spectrum antibiotic therapy advocated a major shift in practice. This study sought to assess the impact of the 2011 PIDS/IDSA guidelines on antibiotic prescribing for children hospitalized with CAP at 3 U.S. children’s hospitals. Because hospital-level efforts have been shown to be important for guideline implementation and altering prescribing practices, we also explored the impact of guideline-related, individual hospital-based initiatives.

**METHODS**

**Study Population**

This study was nested within the Centers for Disease Control and Prevention (CDC) Etiology of Pneumonia in the Community (EPIC) study, a prospective, population-based, active surveillance of CAP hospitalizations among children (<18 years old) conducted between January 1, 2010, and June 30, 2012, in 3 US hospitals (Le Bonheur Children’s Hospital, Memphis, Tennessee; Primary Children’s Medical Center, Salt Lake City, Utah; and Monroe Carell Jr. Children’s Hospital at Vanderbilt, Nashville, Tennessee). Informed consent was obtained before enrollment. The study protocol was approved by the institutional review board of each study hospital and the CDC.

Children were enrolled in the EPIC study if they resided in a predefined catchment area and were hospitalized at a study hospital with (1) signs or symptoms of acute infectious illness (eg, abnormal temperature); (2) acute respiratory signs or symptoms (eg, cough); and (3) radiographic evidence of pneumonia. Children with recent hospitalization, significant immunosuppression, cystic fibrosis, and tracheostomy were excluded. Those with a clear alternative diagnosis (eg, acute pulmonary embolism) were also excluded. To standardize the determination of radiographic CAP, enrollment films were independently reviewed by a study radiologist at each site. For this study, the EPIC cohort was further restricted by excluding children <3 months of age and those not receiving antibiotics. Child and/or caregiver interviews (collecting sociodemographic characteristics, medical history, and history of present illness) and detailed medical record reviews (capturing medical history and hospitalization course and outcomes, in-hospital antibiotic usage, and laboratory data) were conducted for all enrolled children.

**Outcomes**

The primary outcome was the monthly percentage of children treated with a third-generation cephalosporin, including ceftriaxone, cefotaxime, or cefdinir. For each calendar month, this percentage was calculated by dividing the number of children receiving a third-generation cephalosporin with or without a macrolide during the first 2 days of hospitalization by the total number of enrolled children with CAP. Because the guidelines recommended the use of parenteral penicillin or ampicillin (or oral amoxicillin), we also evaluated the monthly percentage of children receiving these agents with or without a macrolide during the first 2 hospital days as a secondary outcome. We also examined trends in concurrent use of macrolides. Children receiving both a third-generation cephalosporin and penicillin/ampicillin and those receiving other antibiotics during the first 2 days of hospitalization were included for descriptive purposes only, because use of these agents would likely be reserved for circumstances that fell outside the scope of our study.

**Exposure**

The study exposure was time from the release of the PIDS/IDSA guidelines, expressed in months. Electronic publication of the guideline occurred on August 30, 2011, followed by print publication on October 1, 2011. EPIC enrollment encompassed 30 months from January 2010 through June 2012. The study period was divided into preguideline (20 months before September 1, 2011) and postguideline (9 months starting...
on October 1, 2011) periods. September 2011 was considered a transition period and excluded from analyses.

**Statistical Analysis**

We assessed the impact of the PIDS/IDSA CAP guidelines on empirical antibiotic selection using an interrupted time-series analysis, the reference standard for evaluating the impact of policies or programs.\textsuperscript{18,19} Segmented linear regression models were used to determine trends in the monthly percentages of children receiving third-generation cephalosporins or penicillin/ampicillin during both the pre- and postguideline periods. Autoregressive integrated moving average models were used to account for first-order autocorrelation in the error terms of consecutive observations. Because observations may be clustered at the hospital level, we used robust estimators of variance. We also seasonally adjusted the estimates because of known increases in pneumonia incidence during winter months.\textsuperscript{20} This same approach was used for our exploration of trends in concurrent macrolide use.

We anticipated a gradual uptake of the PIDS/IDSA guideline recommendations. Therefore, to quantify the cumulative impact of the guidelines and hospital-based efforts on empirical antibiotic selection, we compared the observed antibiotic prescribing by the end of the study period (9 months postguideline) with the expected antibiotic prescribing by the end of the study period had the guideline not been released (projected trend from the preguideline period).\textsuperscript{18,19}

Sensitivity analyses to assess the robustness of our findings included restricting the cohort to children with independent radiographic confirmation of pneumonia (all children enrolled in the EPIC study had a chest radiograph consistent with pneumonia, although 10% lacked independent radiographic confirmation by a study radiologist), as well as analyses adjusting for temporal changes (aggregated by unit of analysis) in the proportion of children younger than 5 years, with comorbidities, direct admission to intensive care, presence of effusion on admission chest radiograph, and median length of hospital stay.

Subgroup analyses by hospital were also conducted to evaluate the potential differential impact of the PIDS/IDSA guidelines through individual hospital-level guideline-related initiatives. To assess for hospital-level efforts in response to publication of the PIDS/IDSA guidelines, we queried investigators from each study site (randomly designated as Hospitals A, B, and C) regarding the nature and timing of organized hospital-level activities pertaining to dissemination of the guidelines (eg, education campaigns) as well as other general activities related to antibiotic use (eg, antimicrobial stewardship program, local CAP clinical practice guidelines, or CAP order sets).

**RESULTS**

**Characteristics of the Study Population**

There were 2628 children with CAP enrolled in the EPIC study. We excluded 507 children (19%) who did not receive antibiotics or were <3 months of age; 2121 children constituted the final study population. The median number of children enrolled in each month of the study was 65 (interquartile range [IQR] 47–93). Median age was 2 years (IQR 1–6); 55% were male; 56% were white; and 18% were Hispanic. Fifty-two percent of children had ≥1 comorbidities (asthma [34%] was most common). The baseline characteristics of enrolled children were similar before and after the release of the guidelines, with only minor differences noted between the periods (Table 1). Characteristics of the study population at each of the 3 study hospitals are shown in Table 2.

**Antibiotic Prescribing in the Preguideline Period**

In the preguideline period, third-generation cephalosporins were the most commonly prescribed antibiotic class for children at all 3 hospitals (range 43%–61%), whereas penicillin/ampicillin was much less commonly prescribed (range 1%–9%); concurrent macrolide use was more common among those receiving third-generation cephalosporins (Table 2). Overall, Hospital A had the highest proportion of children receiving third-generation cephalosporins and the lowest proportion of children receiving penicillin/ampicillin.

**Changes in Antibiotic Prescribing after Publication of PIDS/IDSA Guidelines**

During the preguideline period, use of third-generation cephalosporins and penicillin/ampicillin was stable, with monthly median proportions of 52.8% (IQR 47.8%–56.6%) and 2.7% (IQR 2.1%–7.0%), respectively (Fig 1). During the postguideline period, the proportion of children who received empirical treatment with third-generation cephalosporins progressively declined, whereas penicillin/ampicillin use increased. By the end of the study period, and compared with the expected use estimated from the preguideline trend, we noted an absolute decrease of −12.4% (95% confidence interval [CI] −19.8% to −5.1%) for third-generation cephalosporin use and an absolute increase of 11.3% (95% CI 4.4% to 18.3%) for penicillin/ampicillin use (Table 3). Results from more complex models and sensitivity analyses were essentially identical.
to our main findings (Table 4). An exploration of concurrent macrolide use with either a third-generation cephalosporin or penicillin/ampicillin demonstrated an increasing trend in the preguideline period and a decreasing trend in the postguideline period, resulting in an absolute decrease of $-14.4\%$ (95\% CI $-23.6\%$ to $-5.2\%)$ by the end of the study period (Supplemental Fig 2). Macrolide monotherapy was uncommon in both the preguideline (3.5\%) and postguideline (4.4\%) periods. Prescribing of other antibiotic agents was also relatively stable (data not shown).

**PIDS/IDSA Guidelines Dissemination and Subgroup Analyses by Hospital**

Within 4 months of their release, the PIDS/IDSA prescribing recommendations were highlighted during 1 or more pediatric departmental educational conferences at hospitals B and C (Table 2). In addition, at Hospital B, the recommendation for penicillin/ampicillin use was endorsed by the Infectious Diseases Division and was disseminated to all pediatric faculty by E-mail. Hospital A did not implement formal dissemination efforts after the release of the guidelines during the study period. All 3 hospitals reported the presence of an antimicrobial stewardship program, although none specifically targeted CAP or restricted the use of third-generation cephalosporins, aminopenicillins, or macrolides. Hospitals B and C reported the presence of a stewardship program continuously during the EPIC study period, whereas Hospital A’s program was established in July 2011. Hospitals A and B reported the presence of an electronic order set for CAP that recommended third-generation cephalosporin therapy for the duration of the EPIC study period; Hospital C did not have a CAP order set. None of the hospitals had a local CAP practice guideline during the study period.

By the end of the EPIC study, and compared with the expected antibiotic use from the preguideline period, all study hospitals showed declining trends in the use of third-generation cephalosporins. However, the declines were statistically significant only in the 2 hospitals that implemented efforts to disseminate the PIDS/IDSA guidelines (Hospital B absolute difference $-27.6\%$ [95\% CI $-43.6\%$ to $-11.7\%$]; Hospital C absolute difference $-17.3\%$ [95\% CI $-29.2\%$ to $-5.4\%$]), whereas in Hospital A the decline in third-generation cephalosporin use was modest and not statistically significant (absolute difference $-8.2\%$ [95\% CI $-23.6\%$ to $7.2\%$]). Hospital B demonstrated a significant increase in penicillin/ampicillin use (absolute difference 20.4\% [95\% CI 10.6\% to 30.3\%]), whereas hospitals A and C showed increases that were not statistically significant (absolute difference 2.0\% [95\% CI $-2.0\%$ to 6.0\%] and 24.1\% [95\% CI $-6.2\%$ to 54.5\%], respectively) (Table 3). We also noted declines in concurrent macrolide use in each of the 3 hospitals, although declines were not statistically significant (Supplemental Table 5).

**DISCUSSION**

Our study demonstrates changes in antibiotic selection among children hospitalized with CAP at 3 U.S. institutions after publication of the PIDS/IDSA guidelines for the management of childhood CAP. Overall, use of third-generation cephalosporins declined significantly after release of the guidelines, whereas penicillin/ampicillin use increased. We noted consistent trends across study sites, although changes were more apparent in institutions that conducted active hospital-based educational efforts to disseminate the PIDS/IDSA guidelines.

Third-generation cephalosporins were the most commonly used antibiotics before release of the PIDS/IDSA guidelines, accounting for approximately half of antibiotic prescribing, with stable rates, during the preguideline period of the study. Their use declined in the postguideline period, accounting for 44.8\% of prescribing by the end of the EPIC study. The use of penicillin/ampicillin increased significantly...
Changes in antibiotic selection after release of the guidelines appear to vary by hospital. Although we could not assess the penetration of formal initiatives or characterize informal activities at each hospital, the 2 institutions that incorporated active, hospital-based educational efforts demonstrated the largest reductions in third-generation cephalosporin use along with the largest increases in penicillin/ampicillin use. At both hospitals, penicillin/ampicillin use was equivalent to third-generation cephalosporin use by the end of the study period. Dissemination efforts at these 2 hospitals were similar and included departmental educational activities shortly after release of the guidelines. In contrast, the hospital without active educational efforts showed more modest declines in prescribing of third-generation cephalosporins and increases in penicillin/ampicillin use that did not reach statistical significance. These findings suggest that active hospital-based efforts are important for rapid implementation of guideline recommendations. However, room for improvement remains. In spite of the observed declines, third-generation cephalosporins were still prescribed for 44.8% of children by the end of the study period (although in some circumstances broader-spectrum therapy was appropriate, eg, critical illness).

Previous studies document wide institutional variability in the management of children hospitalized with CAP.11,25 A phenomenon also observed in our study. Such variation has the potential to contribute to disparities in outcomes, quality of care, and hospitalization costs. The development of consensus national guidelines is a key step toward reducing variation and facilitating best practices. Nevertheless, national recommendations may be

---

### TABLE 2

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Hospital A</th>
<th>Hospital B</th>
<th>Hospital C</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. enrolled</td>
<td>823</td>
<td>666</td>
<td>632</td>
</tr>
<tr>
<td>No. admissions/mo</td>
<td>27 (17, 34)</td>
<td>17 (13, 30)</td>
<td>18 (11, 30)</td>
</tr>
<tr>
<td>Demographics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, yrs</td>
<td>2 (1, 5)</td>
<td>3 (1, 7)</td>
<td>2 (1, 7)</td>
</tr>
<tr>
<td>Male gender</td>
<td>57</td>
<td>53</td>
<td>52</td>
</tr>
<tr>
<td>White race</td>
<td>29</td>
<td>65</td>
<td>84</td>
</tr>
<tr>
<td>Hispanic ethnicity</td>
<td>8</td>
<td>19</td>
<td>30</td>
</tr>
<tr>
<td>Clinical</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any comorbidity</td>
<td>58</td>
<td>57</td>
<td>38</td>
</tr>
<tr>
<td>Direct ICU admission</td>
<td>9</td>
<td>17</td>
<td>13</td>
</tr>
<tr>
<td>Pleural effusion</td>
<td>9</td>
<td>12</td>
<td>23</td>
</tr>
<tr>
<td>Length of stay, h</td>
<td>67 (45, 112)</td>
<td>55 (38, 95)</td>
<td>71 (42, 125)</td>
</tr>
<tr>
<td>Antibiotic therapy preguidelines*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Third-generation cephalosporins (without/with macrolide)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Without macrolide</td>
<td>45</td>
<td>37</td>
<td>33</td>
</tr>
<tr>
<td>With macrolide</td>
<td>15</td>
<td>20</td>
<td>9</td>
</tr>
<tr>
<td>Penicillin/ampicillin (without/with macrolide)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Without macrolide</td>
<td>1</td>
<td>4</td>
<td>9</td>
</tr>
<tr>
<td>With macrolide</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Other β-lactams</td>
<td>5</td>
<td>11</td>
<td>13</td>
</tr>
<tr>
<td>Vancomycin/clindamycin</td>
<td>27</td>
<td>23</td>
<td>24</td>
</tr>
<tr>
<td>Other</td>
<td>6</td>
<td>5</td>
<td>12</td>
</tr>
<tr>
<td>Guideline-related hospital activities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Educational conferences</td>
<td>No</td>
<td>January 18, 2012</td>
<td>November 10, 2011</td>
</tr>
<tr>
<td>Antibiotic recommendations disseminated to faculty</td>
<td>No</td>
<td>April 12, 2012</td>
<td>No</td>
</tr>
<tr>
<td>Other hospital activities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antimicrobial stewardship program</td>
<td>Yes, July 2011</td>
<td>Yes, continuous</td>
<td>Yes, continuous</td>
</tr>
<tr>
<td>CAP clinical practice guideline</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>CAP electronic order set</td>
<td>Yes*</td>
<td>Yes*</td>
<td>No</td>
</tr>
</tbody>
</table>

Values are expressed as median (IQR) or %.

* Median monthly percentage of use during the period preguidelines (January 2010 to August 2011).

* Monotherapy or in combination with other agents.

* Order sets at both institutions recommended third-generation cephalosporins as first-line therapy and did not change during the study period.

---

from a baseline of 2.7% in the preguideline period to 15.2% by the end of the EPIC study. Thus, the observed changes were temporally associated with the publication of the PIDS/IDSA guidelines and consistent with the recommendation of penicillin/ampicillin instead of broader-spectrum third-generation cephalosporins for most children hospitalized with pneumonia. Concurrent macrolide use also declined; macrolides were more commonly combined with third-generation cephalosporins than with penicillin/ampicillin. Although macrolides are often used for presumed atypical CAP, several studies have raised concerns regarding increasing macrolide use and development of antibiotic resistance.21–23 Whereas adult guidelines recommend macrolide/cephalosporin combination therapy for CAP,24 the PIDS/IDSA guidelines do not recommend routine macrolide combination therapy for children. Rather, the guidelines suggest consideration of macrolide combination therapy only in specific circumstances, although this recommendation was rated as weak and based on moderate-quality evidence. Therefore, this decline in concurrent macrolide use may also reflect practice changes as a result of publication of the PIDS/IDSA guidelines.
insufficient to induce rapid practice change. A retrospective study of 38 US children’s hospitals demonstrated only modest increases in PIDS/IDSA guideline-concordant prescribing for CAP at 18 months postguidelines.25 Reasons might include lack of awareness and/or agreement with content, poor evidence quality or ambiguous recommendations, clinical inertia (prior practice), organizational barriers, and absence of consequences for discordant management strategies.26,27 These barriers must be addressed to ensure widespread and effective implementation of guidelines in local environments. Local, hospital-based activities, such as management guidelines and order sets, may improve adherence to national recommendations. A 2012 study of 41 US children’s hospitals reported that less than one-third had a CAP practice guideline.13 Among those hospitals with a guideline recommending penicillin-based therapy (n = 7), 46% of children received penicillin/ampicillin compared with 24% of children at
hospitals without a practice guideline. Multilevel interventions may be most effective for influencing physician prescribing behavior. Ambroggio et al demonstrated that the development of a hospital-based practice guideline, accompanied with an educational campaign and modification of an existing CAP order set, increased guideline-concordant antibiotic prescribing for children hospitalized with CAP from 30% to 100% within 6 months. Importantly, none of the participating hospitals in our study had a hospital-based CAP management guideline during the study period. In addition, existing order sets in hospitals A and B were not modified after release of the PIDS/IDSA guidelines and continued to recommend third-generation cephalosporins. It is likely that additional efforts, such as the introduction of local practice guidelines and revised order sets at the study hospitals, would have prompted more substantial changes in antibiotic prescribing during the study period.

Our findings must be interpreted in light of several limitations. First, this is an ecologic study that evaluated the impact of national guidelines on antibiotic selection for children hospitalized with CAP in real-world settings. We did not randomize hospitals to different interventions and did not analyze individual provider practices to ascertain awareness of the guidelines’ recommendations or individual preferences for antibiotic prescribing. Instead, our analyses used the strongest quasi-experimental design for program/policy evaluations and analyzed data that were prospectively collected and aggregated by month to assess the impact of the guidelines. The EPIC study period allowed us to evaluate early changes up to 9 months after release of the guidelines. Although we documented encouraging and rapid initial changes in antibiotic selection, whether the observed changes were sustained beyond the study period is unknown. We observed a significant change in antibiotic selection closely related to release of the guidelines and in coordination with local efforts; however, the impact of other concurrent interventions cannot be ruled out. Finally, our study is restricted to 3 large academic children’s hospitals that participated in a prospective CDC-sponsored project; our results may not be generalizable to other settings. Nevertheless, our study complements and expands previous retrospective assessments using administrative data, by applying rigorous selection criteria to prospectively identify CAP hospitalizations and collecting detailed hospital-level information of dissemination efforts.

**TABLE 4** Sensitivity Analyses: Reduction in Selection of Third-generation Cephalosporins for Empirical Treatment of Children With CAP After Release of National Guidelines

<table>
<thead>
<tr>
<th>Original and Sensitivity Analyses</th>
<th>Absolute Difference, % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original estimation</td>
<td>−12.4 (−19.8 to −5.1)</td>
</tr>
<tr>
<td>Estimated from last month of preintervention</td>
<td>−10.6 (−16.3 to −5.0)</td>
</tr>
<tr>
<td>Restricted to independently confirmed radiographic pneumoniaa</td>
<td>−16.2 (−25.7 to −6.8)</td>
</tr>
<tr>
<td>Adjusted for proportion &lt;5 yrs old</td>
<td>−13.6 (−27.0 to −0.2)</td>
</tr>
<tr>
<td>Adjusted for total no. of hospitalizations</td>
<td>−13.7 (−21.8 to −5.7)</td>
</tr>
<tr>
<td>Adjusted for proportion with comorbidity</td>
<td>−12.6 (−20.4 to −4.8)</td>
</tr>
<tr>
<td>Adjusted for pleural effusion</td>
<td>−12.9 (−20.3 to −4.9)</td>
</tr>
<tr>
<td>Adjusted for median length of stay</td>
<td>−11.2 (−22.2 to −2.5)</td>
</tr>
<tr>
<td>Adjusted for direct admission to intensive care</td>
<td>−12.7 (−21.8 to −3.7)</td>
</tr>
</tbody>
</table>

Absolute difference was calculated by comparing the observed antibiotic prescribing patterns by the end of the study period (estimated from the postguideline regression model) with the expected antibiotic prescribing by the end of the study period had the guideline not been released (expected use estimated from the preguideline trend).

a All children enrolled in the EPIC study had a chest radiograph consistent with pneumonia, although 10% lacked independent radiographic confirmation by a study radiologist.
of changes in prescribing varied by hospital and were more substantial at those institutions that proactively disseminated the recommendations promoted by the guidelines. Additional studies in a variety of settings are needed to monitor the spread and long-term sustainability of these initial encouraging observations and to identify the most effective hospital-based strategies to facilitate rapid implementation of national guidelines.

ACKNOWLEDGMENTS
The authors thank the children and families who graciously consented to participate in the EPIC study. We also thank Shanda Phillips, RN, BSN, Chris Stockmann, MSc, Jody Cockcroft, BS, CCRP, Lyn Finelli, DrPH, MS, and all of the members of the EPIC team, as well as LeBonheur Children's Hospital, Memphis, Tennessee; Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee; and Primary Children's Medical Center, Salt Lake City, Utah.

REFERENCES
14. McIntosh KA, Maxwell DJ, Pulver LK, et al. A quality improvement initiative to

ABBREVIATIONS
CAP: community-acquired pneumonia
CDC: Centers for Disease Control and Prevention
CI: confidence interval
EPIC: Etiology of Pneumonia in the Community
IDSA: Infectious Diseases Society of America
IQR: interquartile range
PIDS: Pediatric Infectious Diseases Society

FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

FUNDING: Supported in part by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award K23AI104779 to Dr Williams and the Agency for HealthCare Research and Quality under Award 1R03HS022342 to Dr Grijalva. The Etiology of Pneumonia in the Community (EPIC) study was supported by the Influenza Division in the National Center for Immunizations and Respiratory Diseases at the Centers for Disease Control and Prevention through cooperative agreements with each study site and was based on a competitive research funding opportunity. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention or the National Institutes of Health. Funded by the National Institutes of Health (NIH).

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.


Antibiotic Choice for Children Hospitalized With Pneumonia and Adherence to National Guidelines

Derek J. Williams, Kathryn M. Edwards, Wesley H. Self, Yuwei Zhu, Krow Ampofo, Andrew T. Pavia, Adam L. Hersh, Sandra R. Arnold, Jonathan A. McCullers, Lauri A. Hicks, Anna M. Bramley, Seema Jain and Carlos G. Grijalva

Pediatrics; originally published online June 22, 2015;
DOI: 10.1542/peds.2014-3047
Antibiotic Choice for Children Hospitalized With Pneumonia and Adherence to National Guidelines

Derek J. Williams, Kathryn M. Edwards, Wesley H. Self, Yuwei Zhu, Krow Ampofo, Andrew T. Pavia, Adam L. Hersh, Sandra R. Arnold, Jonathan A. McCullers, Lauri A. Hicks, Anna M. Bramley, Seema Jain and Carlos G. Grijalva

Pediatrics; originally published online June 22, 2015;
DOI: 10.1542/peds.2014-3047

The online version of this article, along with updated information and services, is located on the World Wide Web at:
/content/early/2015/06/16/peds.2014-3047